InvaGen (a Cipla subsidiary) Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S.
November 13, 2018 06:30 ET
|
Avenue Therapeutics
Upon first stage closing, InvaGen Pharmaceuticals Inc., a Cipla subsidiary (“InvaGen”), to acquire shares representing a 33.3% stake in Avenue Therapeutics, Inc. (“Avenue”) on a fully diluted basis...
Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
August 14, 2018 07:30 ET
|
Avenue Therapeutics
Company reported positive Phase 3 data in patients with post-surgical pain following bunionectomy Initiation of second pivotal Phase 3 trial expected in the second half of 2018 NEW YORK, Aug. 14,...
Avenue Therapeutics to Participate in JMP Securities Life Sciences Conference
June 19, 2018 08:30 ET
|
Avenue Therapeutics
NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq:ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous...
Avenue Therapeutics to Host Key Opinion Leader Call on Intravenous (IV) Tramadol for the Management of Postoperative Pain
June 06, 2018 08:30 ET
|
Avenue Therapeutics
NEW YORK, June 06, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative Pain
May 21, 2018 06:30 ET
|
Avenue Therapeutics
IV tramadol achieved primary and key secondary endpoints, as well as a clear dose response Initiation of second pivotal Phase 3 trial planned for third quarter of 2018 Management to host conference...
Avenue Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
May 03, 2018 07:30 ET
|
Avenue Therapeutics
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol
March 28, 2018 08:00 ET
|
Avenue Therapeutics
NEW YORK, March 28, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics to Present at March Investor Conferences
March 05, 2018 08:00 ET
|
Avenue Therapeutics
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Highlights
March 01, 2018 07:30 ET
|
Avenue Therapeutics
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics to Participate in Panel on Opioid Abuse at BIO CEO & Investor Conference
February 06, 2018 08:30 ET
|
Avenue Therapeutics
NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...